Method for detection of antigen-specific antibodies in biological samples
View Patent ↗Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.
1. A method for detecting antigen-specific antibodies in a biological sample, wherein the antigen-specific antibodies specifically bind to a target antigen, the method comprising:
(i) providing a modified biological sample from an organism that is suspected of containing antibodies specific for the target antigen, wherein the biological sample from the organism has been modified by exposing it to a labeling agent that adds labels to antibodies that are present in the biological sample;
(ii) contacting target antigen-bound microparticles with the modified biological sample, wherein the target antigen bound-microparticles bind antigen-specific labeled antibodies in the modified biological sample to form microparticle complexes if the antigen-specific antibodies are present in the biological sample; and
(iii) detecting the microparticle complexes, wherein an increase in detection of the microparticle complexes with the antigen-specific labeled antibodies, relative to a reference level of microparticle complexes, indicates the biological sample contains antibodies specific for the target antigen.
2. The method of claim 1 , wherein the labeling agent comprises a first specific binding partner, wherein the first specific binding partner is capable of binding to a second specific binding partner that carries a detectable label, and wherein detecting the microparticle complexes comprises exposing the microparticle complexes to the second specific binding partner that carries the detectable label and detecting a signal from the label if the antigen-specific antibodies are present in the biological sample.
3. The method of claim 2 , wherein the first and second specific binding partners are selected from the group consisting of avidin and biotin.
4. The method of claim 3 , wherein the first specific binding partner is biotin and the second specific binding partner is avidin.
5. The method of claim 4 , wherein providing a modified biological sample comprises biotinylating the biological sample to add a biotin label to the antibodies that are present in the biological sample, and wherein the detectable label is bound to avidin, and the avidin binds to the biotin to add the detectable label to the antibodies that are present in the biological sample.
6. The method of claim 2 , wherein the detectable label is a fluorophore.
7. The method of claim 6 , wherein the first specific binding partner is biotin.
8. The method of claim 1 , wherein the target antigen-bound microparticles comprise the target antigen bound to an antibody that binds the target antigen, and a microparticle coupled to the antibody.
9. The method of claim 1 , wherein the target antigen-bound microparticles comprise a target antigen covalently bound to a microparticle.
10. The method of claim 1 , wherein the biological sample is obtained from a mammalian species, a reptilian species, an avian species, a plant or an insect.
11. The method of claim 10 , wherein the antigen-specific antibody is an engineered antibody.
12. The method of claim 1 , wherein the target antigen is from a pathogen.
13. The method of claim 12 , wherein the pathogen is a virus.
14. The method of claim 13 , wherein the virus is a flavivirus.
15. The method of claim 14 , wherein the target antigen is the flavivirus prM-E protein.
16. The method of claim 1 , wherein the microparticles are polystyrene microspheres, carboxylated microspheres or magnetic beads.
17. The method of claim 1 , wherein the microparticles are about 1 to about 100 microns in diameter.
18. The method of claim 1 , wherein the microparticle complexes are detected using a flow instrument or a plate-based immunological assay.
19. The method of claim 1 , wherein the reference level of microparticle complexes is determined using control antigen-bound microparticle complexes, wherein the reference level of microparticle complexes is determined by contacting target antigen-bound microparticles with a modified negative control biological sample.
20. The method of claim 1 , wherein the biological sample is a bodily fluid sample.
21. The method of claim 1 , wherein the organism is a human subject.
22. The method of claim 1 , wherein the organism is a veterinary subject.
23. A method for detecting antigen-specific antibodies in a biological sample, wherein the antigen-specific antibodies specifically bind to a target antigen, the method comprising:
(i) providing a biotinylated biological sample from an organism that is suspected of containing antibodies specific for the target antigen, wherein biotinylation labels antibodies that are present in the biological sample with biotin;
(ii) contacting target antigen-bound microparticles with the biotinylated biological sample, wherein the target antigen bound-microparticles bind antigen-specific antibodies to form microparticle complexes if the antigen-specific antibodies are present in the biological sample;
(iii) contacting the microparticle complexes with a biotin binding partner conjugated to a detectable label; and
(iv) detecting the microparticle complexes, wherein detection of the microparticle complexes comprising detecting a signal from the detectable label if the antigen-specific antibodies are present in the biological sample, and wherein an increase in detection of the microparticle complexes relative to control microparticle complexes indicates the biological sample contains antigen-specific antibodies.
24. The method of claim 23 , wherein the organism is a human subject.
25. The method of claim 23 , wherein the organism is a veterinary subject.